{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:28:47Z","timestamp":1760236127527,"version":"build-2065373602"},"reference-count":20,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: We aimed to evaluate the effect of intravenous glycoprotein IIb\/IIIa receptor inhibitors (GPIs) on in-hospital survival and mortality during and at the 1-year follow-up in patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI) complicated by cardiogenic shock (CS), who were included in the Polish Registry of Acute Coronary Syndromes (PL-ACS). Methods: From 2003 to 2019, 466,566 MI patients were included in the PL-ACS registry. A total of 10,193 patients with CS received PCI on admission. Among them, GPIs were used in 3934 patients. Results: The patients treated with GPIs were younger, had lower systolic blood pressure on admission, required inotropes and intra-aortic balloon pump (IABP) support more frequently, and showed a lower efficacy of coronary angioplasty. In both groups, the same rates of in-hospital adverse events were observed. A lower mortality rate was reported in the group treated with GPIs 12 months after admission (54.9% vs. 57.9%, p = 0.002). Therapy with GPI was an independent factor reducing the risk of mortality in the 12-month follow-up. Conclusions: The addition of GPIs to the standard pharmacotherapy combined with PCI in patients with MI and CS on admission reduced the risk of death in the 12-month follow-up period without increasing in-hospital adverse event rates.<\/jats:p>","DOI":"10.3390\/jcm10215059","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T22:21:34Z","timestamp":1635805294000},"page":"5059","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["One-Year Outcome of Glycoprotein IIb\/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5564-6920","authenticated-orcid":false,"given":"Krzysztof","family":"Myrda","sequence":"first","affiliation":[{"name":"Silesian Center for Heart Diseases, 3rd Department of Cardiology, 41-800 Zabrze, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"G\u0105sior","sequence":"additional","affiliation":[{"name":"Silesian Center for Heart Diseases, 3rd Department of Cardiology, 41-800 Zabrze, Poland"},{"name":"3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dariusz","family":"Dudek","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, Jagiellonian University Medical College, 31-088 Krak\u00f3w, Poland"},{"name":"GVM Care & Research, Maria Cecilia Hospital, Cotignola, 48033 Ravenna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart\u0142omiej","family":"Nawrotek","sequence":"additional","affiliation":[{"name":"Clinical Department of Interventional Cardiology, John Paul II Hospital, 31-202 Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Niedziela","sequence":"additional","affiliation":[{"name":"Silesian Center for Heart Diseases, 3rd Department of Cardiology, 41-800 Zabrze, Poland"},{"name":"3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Wojakowski","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Structural Heart Diseases, 3rd Division of Cardiology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-2128","authenticated-orcid":false,"given":"Marek","family":"Gierlotka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Opole, 45-040 Opole, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Grygier","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology, Poznan University of Medical Sciences, 61-701 Pozna\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janina","family":"St\u0119pi\u0144ska","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, 04-628 Warszawa, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Witkowski","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology and Angiology, National Institute of Cardiology, 04-628 Warszawa, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2630-5016","authenticated-orcid":false,"given":"Maciej","family":"Lesiak","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology, Poznan University of Medical Sciences, 61-701 Pozna\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Legutko","sequence":"additional","affiliation":[{"name":"Institute of Cardiology, Jagiellonian University Medical College, 31-088 Krak\u00f3w, Poland"},{"name":"Clinical Department of Interventional Cardiology, John Paul II Hospital, 31-202 Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJM199908263410901","article-title":"Early revascularization in acute myocardial infarction compicated by cardiogenic shock","volume":"341","author":"Hochman","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST -segment elevation The Task Force for the management of acute myocardial infarction","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_3","first-page":"1","article-title":"2020 ESCGuidelines for themanagement of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"00","author":"Collet","year":"2020","journal-title":"Eur Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","article-title":"Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study","volume":"108","author":"Peters","year":"2003","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","article-title":"Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"157","author":"James","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1161\/01.ATV.0000223867.25324.1a","article-title":"Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel","volume":"26","author":"Angiolillo","year":"2006","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/1074248415571456","article-title":"Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation","volume":"20","author":"Weeks","year":"2015","journal-title":"J. Cardiovasc. Pharm. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/2048872619894254","article-title":"Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Card","volume":"9","author":"Zeymer","year":"2020","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00228-012-1360-0","article-title":"Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR)","volume":"69","author":"Suk","year":"2013","journal-title":"Eur. J. Clin. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.resuscitation.2019.02.008","article-title":"Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y 12 inhibition from the IABP-SHOCK II trial","volume":"137","author":"Droppa","year":"2019","journal-title":"Resuscitation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1253\/circj.CJ-15-0053","article-title":"Effect of Abciximab Therapy in Patients Undergoing Coronary Angioplasty for Acute ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock","volume":"79","author":"Tomassini","year":"2015","journal-title":"Circ. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.hlc.2017.02.011","article-title":"GPIIb-IIIa Receptor Inhibitors in Acute Coronary Syndrome Patients Presenting With Cardiogenic Shock and \/ or After Cardiopulmonary Resuscitation","volume":"27","author":"Kanic","year":"2018","journal-title":"Heart Lung Circ."},{"key":"ref_13","first-page":"1109","article-title":"What has changed in the treatment of ST\u2014Segment elevation myocardial infarction in Poland in 2003\u20132009 ? Data from the Polish Registry of Acute Coronary Syndromes ( PL\u2212ACS )","volume":"69","author":"Gierlotka","year":"2011","journal-title":"Kardiol. Pol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehi079","article-title":"The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice","volume":"26","author":"Flynn","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_15","first-page":"1502","article-title":"Myocardial infarction redefined\u2014A consensus document of The Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction","volume":"4636","author":"Alpert","year":"2000","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0002-9149(01)02188-9","article-title":"Long-Term Mortality Benefit With the Combination of Stents and Abciximab for","volume":"89","author":"Chan","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0002-9149(02)02487-6","article-title":"Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation","volume":"90","author":"Antoniucci","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0735-1097(00)00814-7","article-title":"Platelet glycoprotein IIb\/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation","volume":"36","author":"Hasdai","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40560-020-00502-y","article-title":"Glycoprotein IIb\/IIIa inhibitors for cardiogenic shock complicating acute myocardial infarction: A systematic review, meta-analysis, and meta-regression","volume":"8","author":"Saleiro","year":"2020","journal-title":"J. Intensive Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ahj.2012.01.014","article-title":"Safety and efficacy of rescue angioplasty for ST-elevation myocardial infarction with high utilization rates of glycoprotein IIb\/IIIa inhibitors","volume":"163","author":"Shugman","year":"2009","journal-title":"Am. Heart J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/21\/5059\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:22:26Z","timestamp":1760167346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/21\/5059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":20,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["jcm10215059"],"URL":"https:\/\/doi.org\/10.3390\/jcm10215059","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2021,10,29]]}}}